Abstract
Mutation analysis by deep sequencing of pancreatic juice in patients with pancreatic ductal adenocarcinoma
Highlights
Reliable methods are needed to identify patients with early-stage cancer or high-grade precancerous lesions in the pancreas
We evaluated the concordance between Gene encoding Kirsten RAS proto-oncogene GTPase (KRAS) and Gene encoding tumor suppressor protein p53 (TP53) mutation profiles in PDAC tissue and pancreatic juice sampled from the distal dilated duct during resection of the primary tumor
Detection of KRAS mutations in the primary tumor From our biobank of pancreatic cancer cases [23,24,25], we identified 21 patients who fulfilled the following criteria: Whipple’s resection performed due to pancreatic head tumor, a verified diagnosis of PDAC, diagnostic FFPE tissue blocks available, and pancreatic juice sample collected during surgery
Summary
Reliable methods are needed to identify patients with early-stage cancer or high-grade precancerous lesions in the pancreas. Around 70% of PDAC cases harbor inactivating TP53 mutations that arise in high-grade PanINs (PanIN-3) before they progress to invasive adenocarcinoma [6, 8] If these and other mutations commonly present in pancreatic cancer or high-grade dysplasia could be reliably detected in pancreatic juice, there might be a potential to identify individuals with early-stage pancreatic cancer or carcinoma in situ before these lesions become visible by imaging. This may provide a window for early medical intervention and a better chance for survival
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
